Novartis/Fougera Pharma

Target: Fougera Pharma
Buyer: Novartis ($NVS)
Price: $1.5 billion
Closed: July 23, 2012

Novartis wanted more skin in the generics game, and it got it in specialty dermatology drugmaker Fougera Pharma. By adding Fougera's drugs to the portfolio held by Sandoz, the Swiss company's generics unit, it suddenly was the leader in dermatology knockoffs. The deal also promised to add some revenue as Novartis' top drug, Diovan, headed for generic competition irrelevance.

Novartis has plans to expand the business to take advantage of the growing number of branded dermatology drugs going off patent. It also sees opportunities to build it internationally. As Sandoz CEO Jeff George said at the time, "We see great potential to take a business that's a U.S. business and take it globally."

Novartis/Fougera Pharma
Read more on

Suggested Articles

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

AstraZeneca is still stinging after its SGLT2 drug Farxiga was waved off in Type 1 diabetes, but new heart failure data could ease the pain.